BioCryst Pharmaceuticals (NASDAQ:BCRX) Coverage Initiated at Wedbush
Wedbush assumed coverage on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX – Free Report) in a research report report published on Tuesday morning, MarketBeat reports. The brokerage issued an outperform rating and a $15.00 price objective on the biotechnology company’s stock. Wedbush also issued estimates for BioCryst Pharmaceuticals’ Q1 2025 earnings at ($0.06) EPS, Q2 2025 earnings […]
Wedbush assumed coverage on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX – Free Report) in a research report report published on Tuesday morning, MarketBeat reports. The brokerage issued an outperform rating and a $15.00 price objective on the biotechnology company’s stock. Wedbush also issued estimates for BioCryst Pharmaceuticals’ Q1 2025 earnings at ($0.06) EPS, Q2 2025 earnings […]
